Navigation Links
Xenogenics Received Rights to Polyanhydride Compounds Drug Delivery Patent
Date:2/16/2012

WOONSOCKET, R.I., Feb. 16, 2012 /PRNewswire/ -- Xenogenics Corporation, a subsidiary of MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) has exclusive license rights to a polyanhydride compounds drug delivery patent recently granted in Canada.

The patent was granted to Rutgers University this July for polyanhydrides which link low molecular weight drugs containing a carboxylic acid group and an amine, thiol, alcohol or phenol group within their structure into polymeric drug delivery systems. The patent also covers methods of producing polymeric drug delivery systems via these polyanhydride linkers and methods of administering low molecular weight drugs to a host via the polymeric drug delivery systems.

Xenogenics Corporation has exclusively licensed this patent from Rutgers University and believes it has applications in the company's coated cardiac stent business and other therapeutic applications which may be attractive to the pharmaceutical industry.

Xenogenics Corporation is a majority-owned subsidiary of MultiCell Technologies, Inc., which  is developing novel therapeutics and discovery tools that address unmet medical needs.  For more information about Xenogenics Corporation and MultiCell Technologies, please visit http://www.xenogenicscorp.com and http://www.multicelltech.com.

Caution Regarding Forward-Looking Statements

Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act").  These statements are often, but not always, made through the use of words or phrases such as "believe", "will", "expect", "anticipate", "estimate", "intend", "plan", "forecast", "could", and "would". MultiCell bases these forward- looking statements on current expectations about future events.  They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement.  Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize our products as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations.  For additional information about risks and uncertainties MultiCell faces, see documents that MultiCell files with the Securities and Exchange Commission, including MultiCell's report on Form 10-K for the fiscal year ended November 30, 2010, and all of MultiCell's quarterly and other periodic SEC filings.  MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and assumes no obligation and expressly disclaims any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.

 


'/>"/>
SOURCE MultiCell Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Xenogenics Corporation Retains the Emmes Group to Advise on Fund Raising Efforts
2. Excellent Results Received from GeoVaxs Full-Dose HIV/AIDS Vaccine Trial
3. Long-Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax(R)-Brain
4. Galderma Received FDA Approval of Differin(R) (adapalene) Lotion, 0.1%, the First Retinoid Available in Lotion Formulation
5. Lotus Pharmaceuticals Laevo-Bambuterol Received SFDA Approval to Commence Clinical Trials
6. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
7. Disseminated Adenovirus Infection Eradicated in a Pediatric Hematopoietic Stem Cell Transplantation Recipient Who Received Chimerixs Lead Antiviral CMX001
8. Morphotek, Inc. Announces That Two Investigational Drugs Have Received Orphan Drug Designations
9. Solta Medical Reports FDA Clearance Received for Second Generation LipoSonix® System
10. China Medical Technologies Recently Received Approximately 2,200,000 of its ADSs from Two Banks which Borrowed the ADSs in Connection With the Issuance of the Companys Convertible Notes in August 2008
11. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... 28, 2017 The global ... 8.0 billion by 2025, according to a new study ... infectious diseases and cancer is expected to upsurge the ... over the coming years. In addition, higher number of ... allogenic stem cell therapy, due to adverse effects caused ...
(Date:3/28/2017)... CAMBRIDGE, England , March 28, 2017 ... in collaborative research with Cambridge ... Milner Therapeutics Consortium   The Milner Therapeutics Institute ... Therapeutics Consortium. Elysium Health has committed significant investment for collaborative ... over the next four years. This is the first major ...
(Date:3/27/2017)... LONDON , March 27, 2017 ... require to better understand Bayer and its partnering interests and ... since 2010 report provides an in-depth insight into the partnering ... On demand company reports are prepared upon purchase ... and company data. The report will be delivered ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... 2017 , ... Usually, the impending arrival of warmer weather means the gleeful ... a double chin, this means more anxiety than elation. The cosmetic dermatology experts at ... a double chin is undesirable,” Dr. Goldman said, “but it seems doubly so when ...
(Date:3/28/2017)... Conn. (PRWEB) , ... March 28, 2017 , ... ... based in Wethersfield, Conn., has relocated its corporate headquarters to a new, more ... clients. , In October 2016, Qualidigm purchased a distressed office building in ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... plans work, the Self-Funding Success website has recently developed and published an informational ... Plans ” was created based on common inquiries the site’s team of third ...
(Date:3/28/2017)... CA (PRWEB) , ... March 28, 2017 , ... ... which will be offered by the American Association of Integrative Medicine and available ... for healthcare providers at the AutismOne 2017 Conference in Colorado Springs. , Ed ...
(Date:3/28/2017)... ... March 28, 2017 , ... With expansion and efficiency in ... early March. , The seed processing plant opened in Marshallville in 2006, and a ... new office allows opportunity for transition of Patten Seed operations to the Middle Georgia ...
Breaking Medicine News(10 mins):